| Autor: |
Garg M; Merck & Co., Inc., Rahway, NJ 07065, USA., Puckett J; COVIA Health Solutions, Lansdale, PA 19446, USA., Kamal-Bahl S; COVIA Health Solutions, Lansdale, PA 19446, USA., Raut M; Merck & Co., Inc., Rahway, NJ 07065, USA., Ryland KE; Merck & Co., Inc., Rahway, NJ 07065, USA., Doshi JA; Division of General Internal Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Huntington SF; Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT 06510, USA. |
| Abstrakt: |
Aim: To examine real-world treatment patterns, survival, healthcare resource use and costs in elderly Medicare beneficiaries with diffuse large B-cell lymphoma (DLBCL). Methods: 11,880 Medicare patients aged ≥66 years with DLBCL between 1 October 2015 and 31 December 2018 were followed for ≥12 months after initiating front-line treatment. Results: Two-thirds (61.2%) of the patients received standard-of-care R-CHOP as first-line treatment. Hospitalization was common (57%) in the 12-months after initiation of 1L treatment; the mean DLCBL-related total costs were US$84,416 during the same period. Over a median follow-up of 2.1 years, 17.8% received at least 2L treatment. Overall survival was lower among later lines of treatment (median overall survival from initiation of 1L: not reached; 2L: 19.9 months; 3L: 9.8 months; 4L: 5.5 months). Conclusion: A large unmet need exists for more efficacious and well-tolerated therapies for older adults with DLBCL. |
